权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Characterization of the New Tumor Suppressor USP9X in Pancreatic Cancer

新型肿瘤抑制剂 USP9X 在胰腺癌中的表征

基本信息

批准号：
9015258
负责人：
Chang-il Hwang
金额：
$ 6万
依托单位：
COLD SPRING HARBOR LABORATORY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-03-01 至 2018-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9015258
关键词：
Adenocarcinoma Cell Adherent Culture Apoptosis Cancer cell line Cause of Death Cell Line Cell Transplants Cells Clinical Deubiquitinating Enzyme Disease Progression Ductal Ductal Epithelial Cell Genetic Genetically Engineered Mouse Health Human In Vitro Individual Insertional Mutagenesis Malignant - descriptor Malignant Neoplasms Malignant neoplasm of pancreas Methods Modeling Modification Molecular Mus Oncogenic Organoids Pancreas Pancreatic Ductal Adenocarcinoma Pathway interactions Patients Pharmaceutical Preparations Phenocopy Play Precancerous Conditions Premalignant Process Property Proteins Proteome Proteomics Reaction Research Resistance Role Sleeping Beauty Structure Survival Rate System Testing Time Transplantation Tumor Suppressor Proteins Ubiquitin United States Validation anticancer research base biomarker discovery cancer cell gene function genome-wide high throughput analysis human disease improved in vivo in vivo Model monolayer mouse model novel novel therapeutics outcome forecast pancreatic cancer cells response screening therapeutic target three dimensional cell culture tissue culture tumor tumor progression ubiquitin-protein ligase

项目摘要

DESCRIPTION (provided by applicant): Characterization of the tumor suppressor Usp9x in pancreatic ductal organoids and pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death due to cancer in the United States. The five-year survival rate for PDAC patients is the lowest among common cancers, and remains at only 6% despite intensive efforts to improve clinical prognosis. The conventional tissue culture methods to grow pancreatic cancer cell lines in monolayer allow us to dissect molecular pathways and drug responses in PDAC. However there is a significant translational gap between in vitro and in vivo. For example, when orthotopically injected, PDAC cell lines grown in monolayer do not produce a stromal reaction, unlike tumors from genetically engineered mouse models (GEMMs) or human patients. Moreover it is a daunting task to utilize GEMMs to validate the function of genes and the responses of drugs in a high throughput manner. Therefore, it is urgently required to bridge the gap between in vitro and in vivo models. Here, I propose to establish three dimensional culture and transplantation models to study PDAC progression and characterize gene function in primary pancreatic ductal cells. I have successfully grown murine normal, premalignant and malignant pancreatic ductal epithelial cells in three dimensional semisolid matrices (called pancreatic organoids hereafter) from GEMMs (wild-type, Kras+/LSL-G12D, Pdx1-Cre; Kras+/LSL-G12D or Pdx1-Cre;Kras+/LSL-G12D; Trp53+/LSL-R172H). More importantly, upon orthotopic transplantation, engrafted organoid cells faithfully recapitulate PDAC progression unlike 2D cell lines. Thus, murine orthotopically grafted organoid (OGO) models will provide a unique platform to study PDAC progression, biomarker discovery and functional validation of therapeutic targets. Previously, we have identified the deubiquitinating enzyme, Usp9x as a new tumor suppressor in PDAC using Sleeping Beauty insertional mutagenesis screening. We found that cells lacking Usp9x had an increased resistance to apoptosis following matrix detachment, and we implicated the E3 ubiquitin ligase Itch, a substrate of Usp9x in this process. However, the role of Usp9x and Itch in PDAC remains largely unknown. Using three dimensional pancreatic ductal organoids, I will study the role of Usp9x and its substrate Itch in PDAC progression, allowing us to investigate the role of Usp9x and Itch in normal and premalignant pancreatic ductal cells. Usp9x and Itch have protein targets that can explain their tumor suppressor properties. These target proteins will be identified by whole proteome and Ubiquitin-proteome methods. To characterize the functions of Usp9x and Itch, the role of individual substrates of Usp9x and Itch will be investigated using OGO mice. The newly identified substrates of Usp9x and Itch will elucidate new tumor suppressive pathways in PDAC progression, paving the road towards new therapeutics.